Atenolol exposure and risk for development of adverse metabolic effects: A pilot study

Hrishikesh A. Navare, Reginald F. Frye, Rhonda M. Cooper-DeHoff, Jonathan J. Shuster, Karen Hall, Siegfried O.F. Schmidt, Stephen T. Turner, Julie A. Johnson

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Study Objective. To evaluate whether the level of systemic exposure to atenolol explains observed interindividual differences in adverse metabolic responses. Design. Open-label, prospective, pharmacokinetic pilot substudy of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Setting. General clinical research center. Patients. Fifteen hypertensive adults (mean age 46 ± 8.9 yrs) who were enrolled in the PEAR study. Intervention. Patients received atenolol therapy for at least 8 weeks, with 5 of those weeks at a dosage of 100 mg/day, and then underwent a 2-hour oral glucose tolerance test during a pharmacokinetic study visit. Measurements and Main Results. Twenty-hour plasma atenolol concentrations were measured during the pharmacokinetic visit. Glucose and insulin levels were measured during the 2-hour oral glucose tolerance test, and fasting plasma lipid, glucose, and insulin levels were measured at baseline and after 8 weeks of atenolol treatment. A significant association was noted between atenolol area under the concentration-time curve (AUC) and change in fasting glucose level when adjusted for covariates (p=0.0025); the effect was strongest in women. No significant relationship was noted between plasma atenolol concentration and glucose AUC during oral glucose tolerance testing (r=0.08, p=0.78), nor between atenolol AUC and change in triglyceride levels (r=0.13, p=0.63). Conclusion. Higher plasma atenolol exposure may be a risk factor for an increase in fasting plasma glucose level during atenolol treatment. These findings require confirmation in a larger sample.

Original languageEnglish (US)
Pages (from-to)872-878
Number of pages7
JournalPharmacotherapy
Volume30
Issue number9
DOIs
StatePublished - Sep 1 2010

Keywords

  • Adverse metabolic effect
  • Atenolol
  • Glucose
  • Hypertension
  • OGTT
  • Oral glucose tolerance test
  • Plasma lipid levels
  • β-blockers

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Atenolol exposure and risk for development of adverse metabolic effects: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Navare, H. A., Frye, R. F., Cooper-DeHoff, R. M., Shuster, J. J., Hall, K., Schmidt, S. O. F., Turner, S. T., & Johnson, J. A. (2010). Atenolol exposure and risk for development of adverse metabolic effects: A pilot study. Pharmacotherapy, 30(9), 872-878. https://doi.org/10.1592/phco.30.9.872